Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study

• Published in: Thrombosis and haemostasis Vol. 103; no. 1; p. 213
• Main Authors: Montalescot, Gilles, Sideris, Georgios, Cohen, Remy, Meuleman, Catherine, Bal dit Sollier, Claire, Barthélémy, Olivier, Henry, Patrick, Lim, Pascal, Beygui, Farzin, Collet, Jean-Philippe, Marshall, Debra, Luo, Junxiang, Petitjean, Helene, Drouet, Ludovic
• Format: Journal Article
• Language: English
• Published: Germany 01.01.2010
• Subjects: Acute Coronary Syndrome - blood; Acute Coronary Syndrome - drug therapy; Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Paris; Piperazines - administration & dosage; Piperazines - adverse effects; Platelet Aggregation - drug effects; Platelet Aggregation Inhibitors - administration & dosage; Platelet Aggregation Inhibitors - adverse effects; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes - administration & dosage; Thiophenes - adverse effects; Ticlopidine - administration & dosage; Ticlopidine - adverse effects; Ticlopidine - analogs & derivatives; Time Factors; Treatment Outcome; Paris

Compared with the approved dose regimen of clopidogrel (300-mg loading dose [LD], 75-mg maintenance dose [MD]), prasugrel has been demonstrated to reduce ischaemic events in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). In ACS, antiplatelet effects...